에 대한 최신 뉴스 Incyte (NASDAQ:INCY) 주식

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Equities

Government

Large Cap

Macro Notification

Mid Cap

Broad U.S. Equity ETFs

Small Cap

Markets

Movers

Tech

ETFs

ANET

AVGO

ETSY

GNRC

INCY

NVDA

PARA

QRVO

SIRI

SMCI

TEAM

TSLA

XLRE

Select Sector SPDR-Consumer Discretionary

기술주가 시장 상승세를 주도함에 따라 나스닥 100 지수는 목요일에 4일 연속 올랐다. 이 지수는 0.6% 오른 19,576포인트로 마감하며 사상 최고치를 경신했다.S&amp;P 500 지수도 4일 연속 올랐다. 목요일 이 지수는 0.2% 상승해 사상 최고치인 5,433포인트를 기록했다. 실망스러운 실업 수당 청구 데이터로 인한 오전 하락세에서 반등했다.

나스닥 100, S&amp;P 500은 기술주가 우위를 되찾으며 사상 최고치로 마감: 상승주와 하락주

Incyte Corp

INCYTE ORD

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $71.82, a high estimate of $92.00, and a low estimate of $60.00. This upward trend is evident, with the current average reflecting a 2.73% increase from the previous average price target of $69.91.
<img src="https://www.benzinga.com/files/images/story/2024/1727787645_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Incyte among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$74.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$66.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Incyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Incyte's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Incyte's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Incyte analyst ratings.</a>
<h2>Unveiling the Story Behind Incyte</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Breaking Down Incyte's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.34%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Incyte's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -42.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -10.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Incyte's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.54%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Incyte: Insights From 11 Financial Analysts

Wolfe Research analyst Andy Chen initiates coverage on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Outperform rating.

News

Initiation

Wolfe Research Initiates Coverage On Incyte with Outperform Rating

On Friday, Aquestive Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) hosted a virtual investor day highlighting the company&#8217;s Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41065740/aquestive-therapeutics-spotlights-its-innovative-epinephrine-delivery-pipeline-at-virtual-investor" rel="noreferrer noopener">Topical Gel</a>.
Aquestive said it completed enrollment in its remaining supportive study for Anaphylm, the oral allergy syndrome (OAS) challenge study. Following the completion of dosing, the study is expected to be completed in the fourth quarter of 2024.
The company remains on track to hold the FDA pre-New Drug Application (NDA) meeting in the fourth quarter of 2024.
Aquestive remains focused on completing an NDA submission with the FDA in the first quarter of 2025 and initiating a full product launch of Anaphylm, if approved by the FDA, at the end of 2025 or in the first quarter of 2026.
The company completed its first human clinical study for AQST-108 and plans to develop AQST-108 for Alopecia areata (patchy hair loss), which impacts as many as 6.7 million people in the U.S.
The company expects to hold a pre-Investigational New Drug (IND) meeting with the FDA in the first quarter of 2025 and to commence the Phase 2 study in the second half of 2025.
H.C. Wainwright raised the price target for Aquestive Therapeutics to $10 from the prior $9 per share <a target="_blank" href="https://www.benzinga.com/quote/AQST/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>, reflecting the addition of AQST-108 to the valuation assessment.
The analyst attributes a 30% probability of approval to AQST-108 for Alopecia areata and an 85% probability to Anaphylm for anaphylaxis.
In June 2022, the FDA approved Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) / Incyte Corporation&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) oral Olumiant (baricitinib) for adults with <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/22/06/27704671/approval-of-baricitinib-for-patchy-baldness-validates-clinical-patch-for-this-small" rel="noreferrer noopener">severe alopecia areata</a>.
Just a year after, in June 2023, the FDA <a target="_blank" href="https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and" rel="noreferrer noopener">approved</a> Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) oral Litfulo&nbsp;(ritlecitinib) for individuals 12 years of age and older with <a target="_blank" href="https://www.benzinga.com/general/biotech/23/06/33001406/pfizers-litfulo-scores-fda-approval-as-first-alopecia-treatment-for-adolescents" rel="noreferrer noopener">severe alopecia areata</a>.
Given the steep list prices of treatments like Litfulo, which costs around $49K per year, Aquestive expects a topical alopecia areata treatment without a black box warning to capture significant market share if priced at a 25% discount to JAK inhibitors.
If approved, the analyst anticipates that AQST-108 could be priced at approximately $37K annually. Even with peak market penetration rates below 2%, the drug is projected to surpass $1 billion in annual U.S. sales.
Price Action: AQST stock is up 6.14% at $5.01 at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41100250/bridgebio-pharmas-lead-candidate-cuts-mortality-related-hospitalizations-in-patients-with-certain" target="_blank" rel="noreferrer noopener">BridgeBio Pharma&#8217;s Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease</a>.</li>
</ul>

Analyst Color

Biotech

Health Care

Price Target

Trading Ideas

General

AQST

Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate

SNDX

Incyte, Syndax Report Publication Of Data From Pivotal AGAVE-201 Trial Of Niktimvo; Trial Met The Primary Endpoint Across All Cohorts

Truist Securities has downgraded Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), noting Jakafi&#8217;s (ruxolitinib) patent loss <a target="_blank" href="https://www.benzinga.com/quote/INCY" rel="noreferrer noopener">approaching in 2028</a>.
Jakafi is Incyte&#8217;s top-selling drug. It is indicated for polycythemia vera in adults, intermediate or high-risk myelofibrosis in adults, and steroid-refractory acute graft versus host disease in adult and pediatric patients.
In second quarter 2024, the drug generated sales of&nbsp;$705.9 million, +3% year-over-year, driven by a 9% <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40045943/incytes-q2-earnings-wider-than-expected-loss-pipeline-review-lifts-jakafi-sales-gui" rel="noreferrer noopener">increase in paid demand</a>.
The analyst downgraded the stock from Buy to Hold, with a price target of $74, <a target="_blank" href="https://www.benzinga.com/quote/INCY/analyst-ratings" rel="noreferrer noopener">down from $83</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40417124/incyte-seeks-expanded-fda-approval-for-lymphoma-drug-after-releasing-promising-topline-data-from-" rel="noreferrer noopener">Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study</a>.
With Jakafi&#8217;s loss of exclusivity approaching, a key concern is whether Incyte&#8217;s pipeline in immunology, inflammation (I&amp;I), and oncology can compensate for the revenue decline expected from generic competition. While there is long-term growth potential in the company&#8217;s pipeline—supported by strong Phase 2 data and opportunities for expansion into new indications or combination therapies—the challenge of mitigating the patent cliff remains significant.
Additionally, Incyte faces intense competition, particularly in larger markets where it aims to establish a foothold, such as I&amp;I and solid tumors.
Truist emphasizes the significance of the late-stage results for Povorcitinib in hidradenitis suppurativa (HS), expected in the first half of 2025, as a key factor likely to influence stock performance over the next 12 months.
Additionally, the analyst draws attention to the earlier-stage results expected in the second half of 2024 for Zilurgisertib in myelofibrosis. However, due to Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) delays and the challenges, combined with the early development stage of Incyte&#8217;s programs, Truist is adopting a more cautious stance.
Price Action: INCY stock is down 0.93% at $65.81 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40923696/general-motors-boosts-ev-charging-access-17-800-tesla-chargers-now-open-for-all-gm-drivers-with-" target="_blank" rel="noreferrer noopener">General Motors Boosts EV Charging Access: 17,800 Tesla Chargers Now Open For All GM Drivers With New Adapter</a>.</li>
</ul>

Downgrades

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets

Truist Securities analyst Srikripa Devarakonda downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Hold and lowers the price target from $83 to $74.

Truist Securities Downgrades Incyte to Hold, Lowers Price Target to $74

JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Market Perform.

Reiteration

JMP Securities Reiterates Market Perform on Incyte

WIIM

Incyte shares are trading higher after B of A Securities and Guggenheim raised their respective price targets on the stock.

Guggenheim analyst Michael Schmidt maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Buy and raises the price target from $86 to $92.

Guggenheim Maintains Buy on Incyte, Raises Price Target to $92

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Neutral.

Cantor Fitzgerald Reiterates Neutral on Incyte

B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Neutral and raises the price target from $66 to $68.

B of A Securities Maintains Neutral on Incyte, Raises Price Target to $68

<ul>
<li>Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel)</li>
<li>Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for retifanlimab in SCAC by year-end 2024</li>
</ul>

Reported Saturday, Incyte Announced Results From Phase 3 POD1UM-303/InterAACT2 Trial Of Retifanlimab (Zynyz) In Combination With Platinum-based Chemotherapy (Carboplatin–Paclitaxel) For Inoperable Locally Recurrent Or Metastatic Squamous Cell Anal Carcinoma

<ul>
<li>New antitumor response data from a range of doses and regimens unveiled today at Incyte investor event</li>
<li>These results build upon safety and tolerability data presented earlier today during a mini-oral presentation at the European Society of Medical Oncology (ESMO) Congress 2024</li>
<li>Findings support the initiation of a pivotal trial in ovarian cancer, expected to begin in 2025; additional plans to evaluate INCB123667 in combination with other treatments are underway</li>
</ul>

Reported Saturday, Incyte Unveils Results For CDK2 Inhibitor INCB123667 In Advanced Solid Tumors, Ovarian Cancer Among Highlighted

Discovered By Incyte And Licensed To Lilly, Baricitinib Is For The Treatment Of Rheumatoid Arthritis, Alopecia Areata, Atopic Dermatitis, And Covid-19.

Contracts

Eli Lilly And EVA Pharma Entered Into An Agreement To Expand Access To Baricitinib To An Estimated 20,000 People In 49 Low- To Middle-income Countries In Africa By 2030

Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $67.11, a high estimate of $88.00, and a low estimate of $48.00. This upward trend is evident, with the current average reflecting a 3.07% increase from the previous average price target of $65.11.
<img src="https://www.benzinga.com/files/images/story/2024/1725375621_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Incyte by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>James Shin</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$66.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$48.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Incyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Incyte's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Incyte analyst ratings.</a>
<h2>Discovering Incyte: A Closer Look</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>A Deep Dive into Incyte's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.34%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Incyte's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -42.6%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -10.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.54%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Incyte's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and maintains $67 price target.

RBC Capital Reiterates Sector Perform on Incyte, Maintains $67 Price Target

- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz&#xAE;) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year end 2024
- Mini oral presentation to highlight initial Phase 1 data from potential first-in-class CDK2 inhibitor program in patients with CCNE1 ovarian and other advanced cancers
- Incyte to host an in-person analyst and investor event to review key data at ESMO, including new results from a later CDK2 data cut-off, on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST)
Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.

Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024

On Friday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituximab compared with lenalidomide alone as an add-on to rituximab in patients with relapsed or refractory follicular lymphoma or relapsed or refractory nodal, splenic or extranodal <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40405854/incyte-announces-positive-topline-results-from-pivotal-study-of-tafasitamab-monjuvi-in-relapsed-or" rel="noreferrer noopener">marginal zone lymphoma (MZL)</a>.
The study enrolled 654 adults.
The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment in follicular lymphoma.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40396645/fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-" rel="noreferrer noopener">FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication</a>.
It also met key secondary endpoints of PFS in the overall population by investigator assessment and the positron-emission tomography-complete response rate in the FDG-avid FL population.
In addition, the secondary endpoint of PFS results by the blinded independent review is consistent with investigator-based PFS results.
No new safety signals with <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40045943/incytes-q2-earnings-wider-than-expected-loss-pipeline-review-lifts-jakafi-sales-gui" rel="noreferrer noopener">tafasitamab were observed</a>.
Follicular lymphoma is the most common indolent, or slow-growing, form of B-cell non-Hodgkin lymphoma (NHL), accounting for approximately 13-26% of overall NHL cases.
There are limited treatment options for the more than 17,000 new cases of relapsed or refractory Follicular lymphoma treated every year in the United States, Europe, and Japan.
Incyte expects to file a supplemental marketing application for tafasitamab by the end of the year for follicular lymphoma patients who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy.
The FDA and the European Medicines Agency approved tafasitamab in combination with lenalidomide in 2020 and 2021, respectively, for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, who are not eligible for autologous stem cell transplant.
Incyte reported second quarter Minjuvi/ Monjuvi sales of $31.12 million, up 136% year over year, following the acquisition of the exclusive global rights to tafasitamab <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40045943/incytes-q2-earnings-wider-than-expected-loss-pipeline-review-lifts-jakafi-sales-gui" rel="noreferrer noopener">in February 2024.</a>
Price Action: INCY stock is up 1.82% at $62.80&nbsp;during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40401143/pepsico-faces-legal-heat-gatorade-protein-bars-criticized-for-excessive-sugar" target="_blank" rel="noreferrer noopener">PepsiCo Faces Legal Heat: Gatorade Protein Bars Criticized For Excessive Sugar</a></li>
</ul>
Photo: Shutterstock

Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study

- Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi&#xAE;) or placebo in combination with lenalidomide and rituximab met its primary endpoint of progression free survival (PFS) in relapsed or refractory follicular lymphoma (FL)
- Based on these results, Incyte expects to file a supplemental Biologics License Application for tafasitamab in combination with lenalidomide and rituximab in FL by the end of the year
Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) today announces positive topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi&#xAE;), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with lenalidomide and rituximab compared to lenalidomide and rituximab alone in patients with relapsed or refractory follicular lymphoma (FL).
The trial met its primary endpoint of progression free survival (PFS) by investigator assessment in FL. It also met key secondary endpoints of PFS in the overall population by investigator assessment as well as the positron-emission tomography-complete response rate in the FDG-avid FL population. In addition, the secondary endpoint of PFS results by blinded independent review are consistent with investigator based PFS results. No new safety signals with tafasitamab were observed.

Incyte Announces Topline Results From Study Of Tafasitamab Met Its Primary Endpoint Of Progression Free Survival In Relapsed Or Refractory Follicular Lymphoma; The Secondary Endpoint Of PFS Results By Blinded Independent Review Are Consistent With Investigator Based PFS Results. No New Safety Signals With Tafasitamab Were Observed

Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $68...

Incyte Pipeline Developments: Balancing Potential and Uncertainty in Analyst Hold Rating

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $80.00. The...

TD Cowen Sticks to Its Buy Rating for Incyte (INCY)

In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Incyte (INCY – Research Report), with a price target of...

Stifel Nicolaus Keeps Their Hold Rating on Incyte (INCY)

Incyte closes 5% higher bolstered by Zynyz data, Guggenheim note

JMP Securities analyst Reni Benjamin has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. Reni Benjamin has given his...

Incyte's Hold Rating: Balancing Drug Pipeline Progress and Market Dynamics

Incyte downgraded at Truist on Jakafi patent cliff

Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today.

Wall Street Lower Ahead Of Interest Rate Move

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Incyte (INCY – Research Report) received a Hold rating and a $74.00 price target from Truist Financial analyst Srikripa Devarakonda yesterday. The ...

Incyte (INCY) was downgraded to a Hold Rating at Truist Financial

ALMS

AMGN

AZNCF

BMYMP

CGON

ELYM

GLAXF

PRTG

Press Releases

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte's Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium

Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

Opinion

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FHTX

NRIX

ONCY

REGN

TSX:ONC

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Gilead Sciences

Genmab

Insmed

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Truist Securities

Guggenheim

B of A Securities

RBC Capital

Deutsche Bank

Incyte Pharms

기술주가 <a href="https://www.benzinga.com/tech" target="_blank" rel="noopener" data-google-interstitial="false">시장 상승세를 주도함</a>에 따라 나스닥 100 지수는 목요일에 4일 연속 올랐다. 이 지수는 0.6% 오른 19,576포인트로 마감하며 사상 최고치를 경신했다.
S&amp;P 500 지수도 4일 연속 올랐다. 목요일 이 지수는 0.2% 상승해 사상 최고치인 5,433포인트를 기록했다. <a href="https://www.benzinga.com/markets/equities/24/06/39310762/producer-inflation-rise-less-than-expected-jobless-claims-soar-thursdays-economic-digest" target="_blank" rel="noopener" data-google-interstitial="false">실망스러운 실업 수당 청구 데이터</a>로 인한 오전 하락세에서 반등했다.
오후에는 재닛 옐런 미국 재무장관이 디스인플레이션의 지속적인 진전에 대해 낙관론을 표명한 후 트레이더들이 위험 자산에 대한 신뢰를 회복했다. 옐런은 노동시장 압박 완화를 언급하면서도 고용시장은 여전히 ​​강세를 유지하고 있다고 강조했다.
시장은 9월 금리 인하 가능성이 70%에 가까울 것으로 예상하고 있으며, 현재 연말까지 50bp(베이시스포인트) 이상의 인하를 책정하고 있다. 이는 두번의 금리 인하에 해당한다.
S&amp;P 500의 11개 부문 중 목요일 실적에서는 기술 부문이 1% 상승했고 그 뒤를 이어 부동산 부문이 0.5% 상승했다. 두 가지 모두 금리 인하에 대한 기대가 높아지면서 뒷받침되었다.
에너지 부문은 0.9% 감소해 가장 큰 부진을 겪었고, 통신 서비스 부문이 0.7% 감소해 그 뒤를 이었다.
<figure class="wp-block-table is-style-stripes">
<table>
<thead>
<tr>
<th>섹터</th>
<th>1일 변동률</th>
</tr>
</thead>
<tbody>
<tr>
<td>기술을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>1.02%</td>
</tr>
<tr>
<td>부동산을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>0.52%</td>
</tr>
<tr>
<td>유틸리티를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>0.19%</td>
</tr>
<tr>
<td>소비자 선택 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>0.13%</td>
</tr>
<tr>
<td>기본소비재를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>0.12%</td>
</tr>
<tr>
<td>소재를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>-0.03%</td>
</tr>
<tr>
<td>헬스케어를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>-0.04%</td>
</tr>
<tr>
<td>파이낸셜 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>-0.10%</td>
</tr>
<tr>
<td>산업을 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>-0.64%</td>
</tr>
<tr>
<td>통신 서비스를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>-0.73%</td>
</tr>
<tr>
<td>에너지를 선택하는 섹터 SPDR 펀드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>-0.93%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">나스닥 100의 상승종 5</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>브로드컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>1,679.29</td>
<td>12.29%</td>
</tr>
<tr>
<td>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>129.37</td>
<td>3.33%</td>
</tr>
<tr>
<td>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>182.33</td>
<td>2.84%</td>
</tr>
<tr>
<td>엑셀론 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>)</td>
<td>35.40</td>
<td>1.86%</td>
</tr>
<tr>
<td>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)</td>
<td>143.08</td>
<td>1.66%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">나스닥 100 하락종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>7.31</td>
<td>-6.40%</td>
</tr>
<tr>
<td>몽고DB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)</td>
<td>218.14</td>
<td>-4.85%</td>
</tr>
<tr>
<td>아틀라시안 코퍼레이션 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>)</td>
<td>156.04</td>
<td>-4.17%</td>
</tr>
<tr>
<td>Z스케일러 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)</td>
<td>181.00</td>
<td>-4.15%</td>
</tr>
<tr>
<td>시리우스 XM 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>)</td>
<td>2.53</td>
<td>-3.93%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 상승종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>수퍼 마이크로 컴퓨터 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)</td>
<td>871.16</td>
<td>12.45%</td>
</tr>
<tr>
<td>브로드컴</td>
<td>1,678.90</td>
<td>12.26%</td>
</tr>
<tr>
<td>아리스타 네트웍스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NASDAQ">ANET</a>)</td>
<td>331.67</td>
<td>6.53%</td>
</tr>
<tr>
<td>인사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)</td>
<td>62.68</td>
<td>4.57%</td>
</tr>
<tr>
<td>코보 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>)</td>
<td>113.36</td>
<td>4.27%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">S&amp;P 500 하락종 상위 5</h3>
<figure class="wp-block-table is-style-stripes">
<table>
<tbody>
<tr>
<td>이름</td>
<td>최신</td>
<td>변동률 %</td>
</tr>
<tr>
<td>파라마운트 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)</td>
<td>10.35</td>
<td>-6.92%</td>
</tr>
<tr>
<td>워너 브라더스 디스커버리</td>
<td>7.31</td>
<td>-6.40%</td>
</tr>
<tr>
<td>엣시 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>)</td>
<td>60.15</td>
<td>-4.93%</td>
</tr>
<tr>
<td>제네락 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>)</td>
<td>136.17</td>
<td>-4.58%</td>
</tr>
<tr>
<td>앨버말 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>108.23</td>
<td>-3.92%</td>
</tr>
</tbody>
</table>
</figure>
지금 읽기: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/06/39317123/goldman-sachs-reaffirms-september-rate-cut-forecast-downplays-feds-hawkish-surprise">골드만삭스, 9월 금리인하 전망 재확인, 연준의 &#8216;매파적 서프라이즈&#8217; 경시</a>
이미지: 셔터스톡

Comments

Incyte

뉴스

에 대한 최신 뉴스 Incyte (NASDAQ:INCY) 주식

목요일, 6월 13, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌